Share This Page
Drug Price Trends for PIRMELLA
✉ Email this page to a colleague
Average Pharmacy Cost for PIRMELLA
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PIRMELLA 7-7-7-28 TABLET | 68180-0892-73 | 0.28496 | EACH | 2025-11-19 |
| PIRMELLA 7-7-7-28 TABLET | 68180-0892-71 | 0.28496 | EACH | 2025-11-19 |
| PIRMELLA 7-7-7-28 TABLET | 68180-0892-71 | 0.29855 | EACH | 2025-10-22 |
| PIRMELLA 7-7-7-28 TABLET | 68180-0892-73 | 0.29855 | EACH | 2025-10-22 |
| PIRMELLA 7-7-7-28 TABLET | 68180-0892-73 | 0.27693 | EACH | 2025-09-17 |
| PIRMELLA 7-7-7-28 TABLET | 68180-0892-71 | 0.27693 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Pirmella (Pirmella): market sizing, pricing benchmarks, and revenue projections for a new women’s health brand
Pirmella is positioned as a women’s health product, but there is no sufficient, citable identification of the drug’s active ingredient, dosage form, NDA/ANDA/BLA number, FDA approval date, strength, manufacturer, or Orange Book/Biologics License listing. Without those anchors, market model inputs (therapeutic category, target patient population, payer mix, launch timing, ASP trajectory, and patent/entry risks) cannot be produced in a complete and accurate way.
What is Pirmella and what active ingredient does it contain?
No complete identification is available to map Pirmella to an FDA-approved product record.
Which FDA submissions cover Pirmella (NDA, ANDA, BLA)?
No citable FDA submission identifier is available for Pirmella.
What dosage forms and strengths are marketed for Pirmella?
No citable dosage form or strength data is available.
What patents protect Pirmella and how long is exclusivity likely to last?
No citable patent estate is available for Pirmella. Without the Orange Book/Biologics listing and patent numbers, exclusivity windows and entry timing cannot be computed.
What is the Orange Book status of Pirmella?
No citable Orange Book listing is available.
When does Pirmella lose exclusivity or patent protection?
No citable expiration dates or pediatric exclusivity terms are available.
What is the Orange Book and FDA regulatory pathway for Pirmella?
No citable regulatory pathway details are available.
Does Pirmella have REMS, pregnancy labeling constraints, or special safety programs?
No citable labeling or REMS data is available.
How does Pirmella compare with competing branded products in women’s health?
No competitor mapping is possible without knowing the mechanism of action, indication, formulation, and route of administration for Pirmella.
Which brands and generics are therapeutically substitutable for Pirmella?
No substitutability mapping is possible.
How do pricing and rebates typically work in this sub-therapy?
No reliable pricing model can be set up without confirming the therapy area and payer reimbursement context.
What is the likely launch pricing strategy for Pirmella (WAC, ASP, and net price)?
No inputs are available to construct a WAC-to-net waterfall (rebates, copay assistance, wholesaler terms), because Pirmella’s FDA-labeled product and contract coverage cannot be identified.
What wholesale acquisition cost (WAC) range is realistic for Pirmella?
No market reference points can be tied to Pirmella.
What net price (ASP) range should be used in a revenue model?
No ASP benchmarks can be assigned.
When could generics or biosimilars enter the market for Pirmella?
No citable exclusivity and no citable Paragraph IV or biosimilar information exists.
Are there pending ANDA filings or Paragraph IV challenges for Pirmella?
No citable litigation or ANDA Paragraph IV data is available.
What settlement agreements could delay generic entry?
No citable settlement data is available.
What patent litigation affects Pirmella and how does it change generic entry risk?
No citable litigation records are available.
Have any generic challengers sued over Pirmella?
No citable case identifiers exist.
Market adoption: how fast can Pirmella reach peak share?
Peak share and uptake curves depend on indication, efficacy claims, dosing convenience, clinician adoption, formulary status, and safety profile. None are citable for Pirmella.
What patient segments would adopt Pirmella first?
No indication and eligibility criteria are citable.
What payer formularies and access barriers will shape adoption?
No payer and formulary data is available.
Price projections for Pirmella: base case, downside, and upside scenarios
A price projection requires at minimum: launch WAC, expected net-to-list discounting, competitive intensity, and entry timing. None can be tied to Pirmella without an FDA product identifier and historical benchmarks for the specific therapy.
Base case net price trajectory
Not computable.
Downside scenario (faster discounting or earlier competitive pressure)
Not computable.
Upside scenario (strong formulary penetration and limited substitution)
Not computable.
Revenue projections for Pirmella: first-year sales to peak-year model
Revenue modeling requires: addressable population, prescription or course volumes, market growth, expected penetration curve, and ASP path. None are citable.
First 12 months after launch
Not computable.
Year 3 to peak-year
Not computable.
Sensitivity to ASP and share
Not computable.
Key Takeaways
- Pirmella cannot be evaluated for market sizing, pricing, exclusivity, or revenue projections without a citable product identity (active ingredient, FDA approval record, dosage form/strength) and its Orange Book/Biologics and patent estate.
- No reliable inputs exist to build a priced adoption model or patent-driven entry timeline for Pirmella.
FAQs
- How do I estimate net price (ASP) from WAC for a new women’s health drug like Pirmella?
- What patent estate details are required to model Paragraph IV risk for Pirmella?
- How do formulary tier placement and prior authorization affect uptake for women’s health products?
- What data points drive adoption curves for hormonal or barrier-delivery therapies in the first 24 months?
- How should a revenue model incorporate discounting changes after generic launch for comparable products?
References (APA)
- No sources were cited because Pirmella’s FDA product record, Orange Book listing, and patent identifiers were not available in the provided information.
More… ↓
